Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | GSDMD | P57764 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10939969 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CYP3A4EHMT2EHMT1ABCB11 | |
| Hydrochloric Acid SCHEMBL17223132 | 0.97 | ALDH1A1 (0.33) | ALDH1A1CYP3A4EHMT2EHMT1ABCB11 | |
| SCHEMBL10872216 | 0.79 | — | — | |
| SCHEMBL8741311 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13584363 | 0.77 | EHMT2 (0.35) | ALDH1A1CYP3A4EHMT2EHMT1ABCB11 | |
| SCHEMBL12603726 | 0.76 | — | — | |
| SCHEMBL8741211 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL13584270 | 0.74 | EHMT2 (0.33) | ALDH1A1CYP3A4EHMT2EHMT1ABCB11 | |
| SCHEMBL20881511 | 0.74 | — | — | |
| SCHEMBL16313556 | 0.74 | CA2 (0.42) | ALDH1A1HTTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8822459-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8618122-B2 | Compound having acidic group which may be protected, and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-8614323-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2657235-A1 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1942108-B1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-0685234-B1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU CO LTD (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-6020317-A | Glycerol derivative, device and pharmaceutical composition | NIPPON SHINYAKU CO. LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0685457-B1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5705188-A | LIPID MIXTURE, ANTITUMOR AGENTS | NIPPON SHINYAKU COMPANY, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0685457-A1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685234-A1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | ALDH1A1 793/4885CYP3A4 3093/4885EHMT2 2892/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | ALDH1A1 334/4885CYP3A4 1461/4885EHMT2 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.